| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 02/26/2003 | CN1398884A Bioactive peptide No.30 |
| 02/26/2003 | CN1398883A Bioactive peptide No.24 |
| 02/26/2003 | CN1398882A Bioactive peptide No.21 |
| 02/26/2003 | CN1398881A Bioactive peptide No.23 |
| 02/26/2003 | CN1398880A Bioactive peptide No.22 |
| 02/26/2003 | CN1398879A Bioactive peptide No.14 |
| 02/26/2003 | CN1398878A Bioactive peptide No.16 |
| 02/26/2003 | CN1398877A Bioactive peptide No.15 |
| 02/26/2003 | CN1398876A Fast peptide-synthesizing process in solution |
| 02/25/2003 | US6525179 Methods and compositions for impairing multiplication of HIV-1 |
| 02/25/2003 | US6525021 Cardioprotection, hypoxia, anoxia or ischemia |
| 02/25/2003 | US6524585 Using the indolicidin analogs to reduce or inhibit microbial growth or survival by contacting an environment with the indolicidin analog |
| 02/25/2003 | US6524582 Methods and compositions for impairing multiplication of HIV-1 |
| 02/25/2003 | US6524554 Radiopharmaceuticals comprised of one to three pentapeptides attached to metal chelator or bonding moiety, to which is attached radioisotope, optionally further comprising linking group between peptides and chelator; bind to tuftsin receptors |
| 02/25/2003 | US6524553 A compound, comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a qinolone nonpeptide, and binds to a receptor that is upregulated during angiogenesis |
| 02/25/2003 | CA2095932C Luteinizing hormone releasing hormone analogs |
| 02/25/2003 | CA2032059C Wound treatment employing biologically active peptides |
| 02/22/2003 | CA2355573A1 Method for the synthesis of peptide salts, their use and the pharmaceutical preparations, containing peptide salts |
| 02/20/2003 | WO2003014724A1 A novel cancer marker and uses therefor in the diagnosis of cancer |
| 02/20/2003 | WO2003014698A2 Biological assay detection method |
| 02/20/2003 | WO2003014158A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 02/20/2003 | WO2003014147A1 Novel depsipeptides and process for preparing same |
| 02/20/2003 | WO2003014146A1 A novel peptide p1 inhibiting differentiation of osteoclasts |
| 02/20/2003 | WO2003014145A2 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | WO2003014144A2 Molecule |
| 02/20/2003 | WO2003014142A2 Phosphorylated histone h2b as an apoptosis marker |
| 02/20/2003 | WO2003014076A2 Bi-directional synthesis of oligoguanidine transport agents |
| 02/20/2003 | WO2003014069A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates |
| 02/20/2003 | WO2003013574A1 Melanin-concentrating hormone antagonists |
| 02/20/2003 | WO2003013571A1 Peptidomimetics of biologically active metallopeptides |
| 02/20/2003 | WO2003013426A2 Multivalent synthetic vaccine for cancer |
| 02/20/2003 | US20030036538 Are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest. |
| 02/20/2003 | US20030036514 Administering one or a mixture of a group of linear oligopeptides having from 7 to 10 units |
| 02/20/2003 | US20030036501 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 02/20/2003 | CA2462200A1 Peptidomimetics of biologically active metallopeptides |
| 02/20/2003 | CA2457437A1 A novel cancer marker and uses therefor in the diagnosis of cancer |
| 02/20/2003 | CA2456964A1 Melanin-concentrating hormone antagonists |
| 02/20/2003 | CA2456881A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 02/20/2003 | CA2456761A1 Novel depsipeptides and process for preparing same |
| 02/20/2003 | CA2456590A1 Biological assay detection method |
| 02/20/2003 | CA2456010A1 Phosphorylated histone h2b as an apoptosis marker |
| 02/20/2003 | CA2455951A1 Bi-directional synthesis of oligoguanidine transport agents |
| 02/20/2003 | CA2455336A1 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | CA2454768A1 Molecule |
| 02/20/2003 | CA2453245A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates |
| 02/19/2003 | CN1398298A Non-endogenous, constitutively activated human G protein-coupled receptors |
| 02/18/2003 | US6521746 Leukotoxin polypeptide fused to gonadotropin releasing hormone/factor multimer; increased immunogenicity |
| 02/18/2003 | US6521598 Peptide consisting of an amino acid sequence 1: SPSVDKARAEL; induces transplant tolerance |
| 02/18/2003 | US6521594 Method and composition for treating thrombosis |
| 02/18/2003 | US6521432 Methods for enhancing the rate of modification of metastable bonds |
| 02/18/2003 | CA2075366C Immunologically active peptides or polypeptides from the parvovirus b19 |
| 02/13/2003 | WO2003012127A2 Assay for identifying inhibitors of hiv rt dimerization |
| 02/13/2003 | WO2003012122A2 Crystallized structure of type iv collagen nc1 domain hexamer |
| 02/13/2003 | WO2003012045A2 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
| 02/13/2003 | WO2003011896A1 Peptides having antiangiogenic activity |
| 02/13/2003 | WO2003011895A2 Compositions and methods for modulation of immune responses |
| 02/13/2003 | WO2003011304A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity |
| 02/13/2003 | WO2003011115A2 Peptide-based multimeric targeted contrast agents |
| 02/13/2003 | WO2002066067A3 Albumin-based drug delivery system and antimicrobial peptides |
| 02/13/2003 | WO2002062810A3 Linkable sialyl lewis x analogs |
| 02/13/2003 | WO2002034283A3 Vegh inhibitors and their use |
| 02/13/2003 | WO2002026778A3 Isolated peptides which bind to hla-c molecules and uses thereof |
| 02/13/2003 | WO2001085763A3 Chimeric peptide immunogens their preparation and use |
| 02/13/2003 | WO2001070772A3 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid |
| 02/13/2003 | US20030032769 Second mammalian tankyrase |
| 02/13/2003 | US20030032599 Inhibiting growth or survival of a microorganism, comprising directly contacting the microorganism with a substance P peptide or a peptide mimetic thereof. |
| 02/13/2003 | US20030032594 Intracellular delivery of biological effectors |
| 02/13/2003 | US20030032593 Transporters comprising spaced arginine moieties |
| 02/13/2003 | CA2456196A1 Compositions and methods for modulation of immune responses |
| 02/13/2003 | CA2455638A1 Peptide-based multimeric targeted contrast agents |
| 02/13/2003 | CA2454753A1 Peptides having antiangiogenic activity |
| 02/13/2003 | CA2451942A1 Crystallized structure of type iv collagen nc1 domain hexamer |
| 02/12/2003 | EP1283216A1 Somatostatin analogues binding to all somatostatin receptor subtypes and their use |
| 02/12/2003 | EP1282643A2 Anti-inflammatory compounds and uses thereof |
| 02/12/2003 | EP1282638A1 Peptides and derivatives thereof showing cell attachment, spreading and detachment activity |
| 02/12/2003 | EP1282437A2 Method for treating cartilage disorders |
| 02/12/2003 | EP1282432A1 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes |
| 02/12/2003 | EP1150942A4 Improved compounds for protein binding |
| 02/12/2003 | EP1135169B1 Use of a pharmaceutical composition comprising an anti-cancer agent and at least a peptide |
| 02/12/2003 | EP1003542B1 Use of substances having oxytocin activity for preparation of medicaments for wound healing |
| 02/12/2003 | EP0871456B1 Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of gvhd |
| 02/12/2003 | EP0865447B1 Cyclic dodecapeptide and process for the preparation thereof |
| 02/12/2003 | CN1396929A Cyclic compound |
| 02/12/2003 | CN1396177A Cyclopeptide compound phakellistatin 12 with anticancer activity |
| 02/11/2003 | US6518412 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 02/11/2003 | US6518397 Pharmaceuticals for modulating hormone responsiveness |
| 02/11/2003 | US6518015 Peptide comprising the sequence CAFRQVC and methods using it |
| 02/11/2003 | CA2216851C Radiolabeled peptides for diagnosis and therapy |
| 02/11/2003 | CA2152667C Bone resorption assay |
| 02/11/2003 | CA2102606C Compositions for the treatment of chronic fatigue syndrome |
| 02/11/2003 | CA2036657C Temporary minimal protection synthesis of lh-rh analogs |
| 02/06/2003 | WO2003010281A2 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
| 02/06/2003 | WO2003010199A2 Identification of specific tumour antigens by means of the selection of cdna libraries with sera and the use of said antigens in diagnostic imaging techniques |
| 02/06/2003 | WO2003010198A1 Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques |
| 02/06/2003 | WO2003010191A1 New cationic peptides of the dermaseptin family isolated from the skin secretion of phyllomedusa hypochondrialis |
| 02/06/2003 | WO2003010190A2 Peptide screen |
| 02/06/2003 | WO2002097134A3 Modified peptide nucleic acid |
| 02/06/2003 | WO2002055543A3 Hybrid peptides for treatment of bacteremia and septicemia |
| 02/06/2003 | WO2002032291A3 Imaging of enzymatic activity |
| 02/06/2003 | WO2002020722A3 Methods and compositions for in vitro targeting |